General
Preferred name
Alrizomadlin
Synonyms
APG-115 ()
APG115 ()
AA-115 ()
P&D ID
PD164883
CAS
1818393-16-6
Tags
available
drug candidate
Drug indication
Prolymphocytic leukaemia
Solid tumour/cancer
Drug Status
investigational
Max Phase
Phase 2
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Alrizomadlin is a highly potent and chemically stable E3 ubiquitin-protein ligase Mdm2 (Hdm2) inhibitor. It is used in the treatment and prevention of osteoarthritis.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
6
Organisms
0
Compound Sets
5
BOC Sciences Bioactive Compounds
ChEMBL Drugs
DrugBank
DrugMAP
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
9
Molecular Weight
641.22
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
8
Aromatic Ring Count
2
cLogP
6.81
TPSA
98.74
Fraction CSP3
0.56
Chiral centers
3.0
Largest ring
6.0
QED
0.33
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Apoptosis
Metabolic Enzyme/Protease
Target
E1/E2/E3 Enzyme
MDM-2/p53
Solubility
Soluble in DMSO
Source data
